SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC), heralded as a paramount innovator in developing broad-spectrum antiviral nanomedicines, has officially communicated that Anil R. Diwan, Ph.D., the dynamic President and Executive Chairman of the Company, is set to deliver a pivotal corporate update during the Spartan Capital Investors Conference. This significant event is scheduled for today, November 4, 2024, at 9:45 am, taking place at the prestigious Pierre Hotel in New York City.
In his presentation, Dr. Diwan is expected to delve into the groundbreaking NV-387, a broad-spectrum antiviral drug candidate stemming from the innovative nanoviricides technology platform. Notably, NV-387 has achieved a significant milestone by completing a successful Phase I clinical trial.
Market analysts predict that the overall market size for such antiviral treatments could surpass a staggering $10 billion by 2027, indicating a burgeoning opportunity for investors and stakeholders alike.
About Spartan Capital Investor Conference 2024
This year’s conference, orchestrated in collaboration with B2i Digital, an eminent digital marketing firm known for its expertise in investor communications, is anticipated to draw attention from over 30 select companies. The agenda will comprise engaging panel discussions, personalized one-on-one meetings, and invaluable networking sessions aimed at fostering meaningful connections between investors and presenters.
For those interested in attending or seeking more information about the event, registration details are available on Spartan Capital’s conference page.
NanoViricides, Inc. (www.nanoviricides.com) is at the forefront of antiviral therapy innovation, developing specialized nanomaterials with the aim of combating viral infections. The unique nanoviricide™ class of products is built upon proprietary intellectual property and technology inherited from TheraCour Pharma, Inc., under the terms of a strategic collaboration.
NanoViricides is committed to advancing its pipeline of drug candidates, with NV-387 as the lead contender targeting a range of viral diseases, including RSV, COVID-19, Long COVID, and Influenza, among others. The company is focused on moving NV-387 into Phase II clinical trials, which could potentially change the landscape of antiviral treatments.
In the fight against COVID-19, NanoViricides is also working on NV-CoV-2, a promising nanoviricide candidate that represents a revolutionary approach in antiviral strategies. Furthermore, NV-CoV-2-R combines NV-387 with remdesivir, providing a dual-action mechanism against the virus, enhancing the therapeutic potential.
The Company is exploring the development of treatments for a range of serious viral diseases, demonstrating a robust commitment to expanding its capabilities in the antiviral space. Additionally, NanoViricides holds exclusive perpetual licenses for a variety of viral diseases, ensuring its competitive edge in this rapidly evolving market.
This announcement includes forward-looking statements that encapsulate the Company’s current expectations regarding forthcoming developments, although actual events could significantly diverge from these projections due to various factors beyond the Company’s control. Such statements should be approached with caution as they involve inherent risks and uncertainties.
For inquiries, you may contact:
NanoViricides, Inc.
[email protected]
Public Relations Contact:
[email protected]
SOURCE: NanoViricides, Inc.
View the original press release on accesswire.com
**Interview with Dr. Anil R. Diwan, President & Executive Chairman of NanoViricides, Inc.**
**Interviewer:** Thank you for joining us, Dr. Diwan. Today, you’re set to present at the Spartan Capital Investors Conference. Can you give us a brief overview of what you plan to discuss?
**Dr. Diwan:** Thank you for having me. I’m excited to share valuable insights about our groundbreaking antiviral drug candidate, NV-387. I will cover our innovative nanoviricides technology platform and the significance of our recently completed Phase I clinical trial for NV-387, which targets a variety of viral diseases.
**Interviewer:** NV-387 has marked a significant milestone. What makes this drug candidate stand out in the crowded antiviral market?
**Dr. Diwan:** NV-387 represents a new class of antiviral treatments that leverages our proprietary nanomaterials technology, which allows for broad-spectrum efficacy. This means it can potentially address multiple viral infections, which is increasingly important in today’s evolving health landscape. The anticipated market for antiviral treatments is projected to exceed $10 billion by 2027, making this an attractive opportunity for investors.
**Interviewer:** The Spartan Capital Investors Conference serves as an excellent platform for networking and sharing ideas. What do you hope to achieve by presenting here today?
**Dr. Diwan:** My goal is to engage with investors and stakeholders who share our vision for innovative healthcare solutions. This event will allow me to discuss our plans for advancing NV-387 into Phase II clinical trials and highlight the broader implications of our research. It’s essential for us to forge connections with those who can champion our mission and support our continued growth.
**Interviewer:** It sounds like a promising future for NanoViricides. Can you also briefly mention any other projects your company is working on?
**Dr. Diwan:** Certainly. In addition to NV-387, we are also developing NV-CoV-2, a nanoviricide specifically targeting COVID-19. Moreover, we are exploring a combination treatment, NV-CoV-2-R, which pairs NV-387 with remdesivir to enhance treatment efficacy against the virus. Our commitment to tackling the viral challenges facing our society remains unwavering.
**Interviewer:** Thank you, Dr. Diwan. We look forward to hearing your presentation and wish you all the best at the conference.
**Dr. Diwan:** Thank you! I appreciate the opportunity to discuss our work, and I’m eager to connect with the investment community.
